Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:55:59.598Z.
Consensus retrieved: 2026-10-06T10:33:28.123Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:55:59.598Z.
Quote observation: 2026-10-06T15:55:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3328ed161ff00c537a80d7dceb604f662f1c22c4e65cb57a824bf36ce3bbbe60
Forward PE Ratio (N/A) = Dated Quote Price ($10.57) / Consensus Forward EPS ($-0.75)
FORWARD PE RATIO
N/A
Corvus Pharmaceuticals, Inc.
Market Cap
$888.80M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $888.80M | N/A |
| Bioventus Inc. (BVS)vs › | $897.66M | 17.01 |
| Arbutus Biopharma Corp (ABUS)vs › | $901.76M | 6.17 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $875.80M | 13.80 |
| HealthStream, Inc. (HSTM)vs › | $914.10M | 42.40 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $860.00M | N/A |
| CeriBell, Inc. (CBLL)vs › | $933.21M | N/A |
| Alumis Inc. (ALMS)vs › | $841.81M | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $839.43M | 15.93 |
| Beta Bionics, Inc. (BBNX)vs › | $839.06M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $10.57, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.75 | $-0.79 – $-0.67 | 5 | n/m |
| 2027-12-31 | $-0.93 | $-1.12 – $-0.70 | 5 | n/m |
| 2028-12-31 | $-0.75 | $-1.41 – $-0.04 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
